An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Subjects were eligible for participation in the study if they met the following criteria: 1. At least 18 years of age at the time of first dosing. 2. Subjects must have given signed informed consent before any study related activities were conducted. 3. Subjects in the United States of America (USA) must have given written authorisation for the release of protected health information in compliance with the Health Insurance Portability and Accountability Act (HIPAA) regulations; subjects in other countries must have provided appropriate authorisation as needed by regulatory authorities in each country. 4. Subjects must have been willing to receive s.c. octreotide injections as rescue medication, as needed to control their symptoms, if any. 5. If female, the subject must not have been pregnant (confirmed by negative pregnancy test) and must have had the following documented via verbally given history: * At least 1 year postmenopausal (natural cessation of menses), or * Surgically sterile (if by tubal ligation, surgery must have been performed more than 3 months prior to entry into the study), or * If the subject was of childbearing potential and sexually active, she must have been using an acceptable form of contraception (oral, injected, transdermal or implanted contraceptives, diaphragm or barrier method with spermicidal and/or intrauterine device); local methods such as condoms or sponges/vaginal tablets were not acceptable forms of contraception. 6. Subjects with…